| Metric | Value (₹ Cr) | vs Q1 FY27 |
|---|---|---|
| Revenue | 1.3K | 2.9% |
| Total Income | 1.3K | 2.9% |
| Expenditure | 1.1K | 0.2% |
| PBT | 180.14 | 132.0% |
| Net Profit | 132.86 | 129.9% |
| OPM | 17.06% | 8.79pp |
| NPM | 10.15% | 5.86pp |
| EPS | 4.33 | 130.3% |
Revenue surge masks margin miss; policy clarity needed for H2
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade B
Revenue/PAT targets beat. EBITDA/NPM guidance missed. Management deferring next quarters' outlook is cautious signal.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
Exceptional topline growth (130% YoY, business doubled) is real and driven by PM Surya Ghar subsidy tailwind + expanded distribution. But Q2 EBITDA margin (17.1%) and PAT margin (10.2%) both undershot prior guidance (18-19% and 11-13%), signalling execution pressure. Inventory explosion (₹910 Cr to ₹1,230 Cr) and negative FCF despite doubled revenue are red flags. Management explicitly deferred H2 guidance, citing regulatory uncertainty on ALMM List-II and PM Surya Ghar 2.0 approval—suggesting confidence is conditional. Hold until clarity emerges on margin recovery and policy tailwinds.
₹1306.8 Cr
Revenue · +130.1% YoY₹132.9 Cr
Reported PAT · +111.2% YoYCompressing
Margins · vs guidance: MixedDid the claims hold up?
Revenue grew 130% to ₹1,307 Cr in Q2
METDelivered ₹1,306.8 Cr, YoY +130.1%; matches management's stated ₹1,307 Cr
EBITDA grew 116% to ₹223 Cr in Q2
METEBITDA implied from 17.1% OPM on ₹1,306.8 Cr = ₹223.2 Cr; YoY growth ~116% matches
PAT doubled, up 111% to ₹133 Cr
METDelivered ₹132.9 Cr, YoY +111.2%; matches mgmt claim within rounding
EBITDA margin sustainable at 18-19% per guidance
OVERSTATEDQ2 delivered 17.1%, below 18-19% guided range; Q1 was 18.9%, so 180 bps QoQ decline
Doubled business in a year
METH1 FY27 revenue ₹2,652 Cr vs full-year FY26 ~₹2,655 Cr; supported
Earnings quality
What changed since the last call
Margin guidance miss, Q2 execution
DowngradeQ2 OPM 17.1% vs 18-19% guidance; NPM 10.2% vs 11-13% guidance. Prior Q1 was 18.9%, so QoQ decline 180 bps. Cited Ratlam ramp overheads, seasonal softness, elevated freight. Guidance now in question.
Revenue growth beat expectations
UpgradeQ2 revenue up 130% YoY vs FY27 full-year guidance of 70%. H1 trajectory shows business can double in a year. Surya Ghar subsidy proving immense tailwind.
Inventory discipline worsened
DowngradeInventory rose ₹320 Cr to ₹1,230 Cr in H1. Post-Bawal fire, buying tubular batteries externally. ALMM List-II pending, so stocking ahead of mandate. WC days fell only 24 despite 130% growth—shows buildup.
Debt & capex trajectory
NeutralNet debt ₹800 Cr (up from ₹600 Cr post-Bawal loss). Ratlam capex ₹184 Cr in H1; total capex ₹661 Cr in H1 vs ₹500 Cr full-year target. On track but consuming cash. Management expects to reduce debt post-insurance claim and as inventory normalizes.
The Q&A
Analysts (IIFL, Spark Capital) pressed hard on margin compression, cash flow, debt, oversupply, and H2 growth. Management partially hedged—acknowledged Ratlam ramp costs and inventory buildup, but deflected margin-recovery timing to Q3 results. On Surya Ghar dependency, explicitly deferred forward guidance until policy clarity. Tone was candid on near-term headwinds but confident on long-term structural growth. Did not break under pressure.
Second half growth guidance — Prithvi Raj, IIFL
PartialWe want to revise guidance after Q3 results. Variable factors like ALMM List-II at the door and PM Surya Ghar 2.0 clarity pending. We will not revise guidance this time, but see more clarity in Q4.
Margin sustainability — Prithvi Raj, IIFL
DodgedIt will be sustainable as per our last guidance, basically.
Cell margins vs peers — Himanshu Bisani, PinPoint X
AnsweredWe are B2C-focused, not pure cell players. We sell DCR, non-DCR, and lithium products. Complete system + service moat sustains margins. Government policy (ALMM List-II, DCR shortages) affects our mix. We want to maintain current margins, not be aggressive.
PM Surya Ghar 2.0 upside — Himanshu Bisani, PinPoint X
PartialWe've been in battery business 30 years. If policy comes, it directly suits us. We think we'll get much better market share than today.
DCR cell sourcing — Shwetha, thoughtPMS
AnsweredAround 70%-80% in-house and 20%-30% DCR from outside.
Subsidy revenue mix — Shwetha, thoughtPMS
AnsweredMore than 50% of our revenue comes from on-grid and DCR-based market.
Capacity and oversupply — Sagar Shah, Spark Capital
AnsweredDCR cell shortage is real. ALMM-2 will shift market to DCR. Panel capacity 3.5 GW + cell 2.2 GW. If ALMM-2 and Surya Ghar 2.0 come, we don't have overcapacity. If deferred, we may source cells externally next year. No overcapacity now.
Expense growth vs revenue growth — Sagar Shah, Spark Capital
AnsweredRatlam facility capitalized Aug '26, so overheads now in opex. Fixed costs spread better next year. Selling/distribution expanded, freight/diesel costs up, deliberate Tier 2-3 brand campaigns.
Cash flow and debt — Sagar Shah, Spark Capital
AnsweredInventory rising due to Bawal fire (now buying tubular batteries externally), ALMM List-II pending (pre-stocking). We expect normalization. Debt for Ratlam capex. Insurance claim on Bawal will come through in FY27, reducing debt. Expect debt rationalization and cash improvement post Q4.
Guidance
FY27 revenue growth 70% (raised from prior 50%)
HighGiven in Q1 FY27 call. H1 achieved 127% growth, well ahead. But Q2 was QoQ -2.9%, suggesting H2 moderation likely.
FY27 EBITDA margin 18-19%
MediumQ2 delivered 17.1%, missing range. Management confident it's 'sustainable' as guided but evidence shows compression. Ratlam ramp cited as temporary.
PAT margin target 11-13% for FY27
MediumQ2 delivered 10.2%, below range. Movement in line with EBITDA margin miss (180 bps QoQ compression flows through P&L).
EBITDA margin sustainable at 18-19%
LowDespite confident tone, Q2 is 120 bps below guidance midpoint. Management deferred H2 guidance revision until Q3 results. Suggests uncertainty.
FY27 capex ₹500 Cr (debt ₹200 Cr + operations ₹300 Cr)
HighH1 capex ₹661 Cr already in place. Ratlam facility ramp (panels, cells, batteries, inverters), Hathras tubular batteries, lithium-ion expansion. On track.
Risks the call surfaced
Policy dependency
High50%+ revenue from PM Surya Ghar Phase 1. Phase 2.0 not approved; if delayed or scope reduced, growth stalls. ALMM List-II mandate Jan 2027 could disrupt supply chain if DCR cell production doesn't scale.
Margin compression
HighQ2 OPM 17.1% down 180 bps QoQ despite 130% revenue growth. Below 18-19% guidance. Ratlam ramp, freight inflation, distribution expansion cited; but no clear path to margin recovery in H2.
Inventory management
HighInventory rose ₹320 Cr (₹910 Cr to ₹1,230 Cr) in H1. Post-Bawal fire, sourcing tubular batteries externally. ALMM List-II pending, so pre-stocking DCR capacity. WC days only improved 24 days despite doubled revenue—signals buildup risk.
Debt escalation
MediumNet debt ₹800 Cr (debt/equity 0.55x). H1 capex ₹661 Cr + WC needs consumed all ₹490 Cr OCF. Debt-to-equity manageable now, but negative FCF can push leverage higher if not corrected.
Competitive intensity
MediumLarge solar module manufacturers (Canadian Solar, JinkoSolar, etc.) and new DCR cell makers entering rooftop market. PM Surya Ghar subsidy attracts competition. Price deflation risk on cells and modules.
Management
Score 7/10. Candid on challenges (Bawal fire, Ratlam ramp costs, inventory buildup); less transparent on margin recovery timeline. Deferred H2 guidance, citing policy uncertainty—cautious but credible. Q2 revenue beat guidance (130% vs 70% FY27 target). PAT beat (111% vs guided 11-13% margin). But EBITDA margin miss (17.1% vs 18-19%) signals execution gap on cost control.
1 · Jan 01, 2027
ALMM List-II mandate: all rooftop solar must use DCR cells. Market will shift; impact unclear.
2 · Gov. decision TBD
PM Surya Ghar 2.0 approval. Phase 1 covered 60+ lakh homes; 2.0 could unlock battery storage subsidy, structural margin lift.
3 · Q3 FY27 (Jan '27)
Results will clarify H2 trajectory, margin recovery, and second-half guidance. Management will update after seeing Q3 data.
Hold until clarity emerges on margin recovery and policy tailwinds.
Record growth, eroding margins—the stock's 29% fall reflects the real story
Fujiyama doubled its annual revenue in six months and beat full-year guidance on the top line. But EBITDA and profit margins both fell short, and the market has already priced in the reset.
₹2,652 Cr
=~Full-year FY26; business doubled in one half
17.1% vs 18.9%
−180 bps; vs 18-19% guided range
10.2%
vs 11-13% target; 90 bps below
Negative
₹490 Cr OCF vs ₹661 Cr capex; WC stress
Fujiyama delivered ₹1,307 Cr revenue in Q2, up 130% YoY and already 87% of its full-year 70% growth target for FY27. The topline beat is emphatic. But profit margins compressed simultaneously. Operating margin fell 180 basis points QoQ to 17.1%, landing 120 bps below the prior 18-19% guidance. Net margin hit 10.2%, also short of the 11-13% target. The disparity is striking: revenues grew 130% YoY, EBITDA only 116%. Operating leverage, which should kick in at doubled scale, went the wrong direction.
Where the margin collapse came from
Management blamed three headwinds on the call. First, the Ratlam facility—a new power electronics, cell, and battery manufacturing hub commissioned August 2026—is absorbing overheads ahead of production ramp. Fixed costs are being expensed, not yet spread across output. Second, freight and diesel costs remained elevated. Third, the company deliberately ramped distribution in Tier 2 and Tier 3 cities, incurring one-time brand and marketing spend. These are largely temporary. The real problem is what the call did not resolve: whether the margin recovery is at hand, or structural.
The Q2 FY27 results also absorbed overheads at the Ratlam facility, incurred ahead of the production ramp-up of our recently commissioned panel and inverter division, which contributed to the moderation in EBITDA margin to 17.1% from 18.1% of Q2 FY26.
What changed on this call
Revenue beat, margin miss. Full-year FY27 guidance was set at 70% growth in the prior Q1 call; Q2 is already running at 130% YoY and won't slow to hit 70% for the year without a severe H2 stall. That upside is real, driven by PM Surya Ghar subsidies—the government covered 60+ lakh households in Phase 1, and Fujiyama's 10,200+ channel partners captured a massive share. But management explicitly deferred H2 guidance revision until Q3 results and policy clarity on two binary events: the ALMM List-II mandate (effective Jan 1, 2027, forcing all rooftop solar to use domestically certified cells) and PM Surya Ghar 2.0 approval (battery storage subsidy under consideration). That hedging tone signals conditional confidence, not outright conviction. Inventory and cash flow deteriorated. Inventory spiked ₹320 Cr in the first half to ₹1,230 Cr. Management attributed this to post-Bawal-fire external battery sourcing and ALMM List-II pre-stocking, but working capital days improved only 24 days (123→99) despite 130% revenue growth—the buildup is real. H1 operating cash flow ₹490 Cr was entirely consumed by capex (₹661 Cr) and working capital needs, leaving negative free cash flow. Debt rose from ~₹600 Cr to ₹800 Cr.
Business doubled in 6 months; structural subsidy tailwind confirmed
Revenue growth 130% YoY vs 70% FY27 guidance; trajectory beats forecasts
Integrated manufacturing moat (cell, panel, inverter, battery) hard to replicate
Distribution scale (10,200+ partners, 25 states) and Tier 2-3 brand trust
EBITDA margin fell 180 bps QoQ; below guidance by 120 bps
PAT margin fell to 10.2%, short of 11-13% target
Inventory up ₹320 Cr in H1; only 24-day working capital improvement despite doubled revenue
Free cash flow negative in H1; debt rose ₹200 Cr
Management deferred H2 guidance; contingent on policy clarity (ALMM, Surya Ghar 2.0)
Bawal battery fire loss (₹143 Cr before-tax) one-time drag; insurance claim pending
Ranked risks—what should concern a holder
Policy dependency—ALMM List-II and PM Surya Ghar 2.0 binary outcomes
High50%+ of H1 revenue from Surya Ghar Phase 1; Phase 2.0 (battery subsidy) not approved. ALMM List-II effective Jan 1, 2027 could disrupt supply if DCR cell production doesn't scale. Revenue cliff if either delayed.
Margin compression amid scaled growth—operating leverage absent
HighQ2 OPM 17.1% vs Q1 18.9% (−180 bps) despite 130% YoY revenue growth. Guidance miss (18-19% range) contradicts confidence in margin recovery. If compression is structural, not cyclical, target multiple compresses further.
Inventory buildup and negative free cash flow—working capital stress
HighInventory ₹1,230 Cr (H1 up ₹320 Cr). H1 OCF ₹490 Cr fully consumed by capex and WC. Negative FCF despite doubled revenue suggests buildup may not convert to cash if demand slows or policy changes.
Debt escalation amid capex cycle and negative FCF
MediumNet debt ₹800 Cr (debt/equity 0.55x, manageable now). But rising debt while FCF is negative is unsustainable if growth moderates or H2 margins deteriorate further.
Competitive entry and price deflation—large module makers entering rooftop market
MediumFujiyama has brand and distribution moat, but Canadian Solar, JinkoSolar, Trina entering rooftop. Subsidy pool is finite; if pricing pressure hits, integrated margin advantage erodes.
How the street is positioning
The stock closed at ₹347.05 on the result (as of 2026-11-13). It is down 29.42% from its all-time high of ₹491.7, but up 101.77% off the 52-week low of ₹172. On the intermediate chart, it sits below both the 20-day and 50-day moving averages (₹366.93 and ₹399.29 respectively) but above the 200-day (₹319.36)—a downtrend in progress. RSI at 39.4 signals neither oversold nor overbought; the trend is neutral. Institutional positioning is cooling. FII ownership fell to 1.13% from 1.63% one quarter ago (−50 basis points), and DII also declined to 5.38% from 5.98% (−60 basis points). Promoter stake remains steady at 86.63% with no insider selling signal. The message: foreign and domestic institutions are trimming despite record growth. The 29% drawdown from ATH is the street's verdict on the margin miss and cash flow stress—record revenue is not compensating for the execution gap.
1 · Jan 1, 2027: ALMM List-II mandate
All rooftop solar must use domestically certified (DCR) cells. Market will shift; Fujiyama's 1 GW DCR capacity (1.2 GW TOPCon on track for Q1 FY28) positions it well. Watch for: supply constraints that support pricing, or rapid capacity additions that commoditize prices. This is a 50-50 binary for margin impact.
2 · Q3 FY27 results (Jan 2027): Margin recovery or further compression
Ratlam facility overheads should normalize; inventory should begin to unwind if Surya Ghar continues; freight may moderate. Management will also update H2 trajectory and provide Q4 guidance. The test: do margins return to 18%+ on mid-quarter volumes, or stay compressed? If compressed, structural thesis breaks.
3 · PM Surya Ghar 2.0 approval (date TBD): Battery storage subsidy
Fujiyama has 30-year battery pedigree and 3 GWh lithium-ion capacity. If Surya Ghar 2.0 includes storage subsidy, the company's integrated system (panel + inverter + battery) becomes the obvious play—likely margin lift and incremental revenue stream. If delayed or capped, growth deceleration likely.
Fujiyama Power Systems delivered a quarter of exceptional topline scale—doubled revenue in a year, beat full-year guidance by 2x. But it came with margins compressed 180 basis points QoQ and free cash flow negative in H1. Management is candid on near-term headwinds (Ratlam ramp, inventory, capex) but deferred forward guidance, citing policy contingencies. The market has already priced in the margin miss; the stock is down 29% from ATH despite record growth. Institutions are trimming positions.
Rating: Hold. The long-term structural thesis—PM Surya Ghar on a 67 GW addressable market, integrated manufacturing moat, distribution scale—is intact. But the near-term execution is at risk. The company needs to prove margin recovery in Q3 (back to 18%+ EBITDA) and show positive cash flow generation to justify ownership. Until the debate between temporary Ratlam ramp costs vs. structural margin compression is resolved, the stock deserves to trade at a discount.
The single number to track from here: Q3 EBITDA margin. If it rebounds toward 18%, the thesis recovers and the 29% drawdown becomes tactical. If it stays compressed below 17%, the bull case needs to be rewritten.